Ladenburg Thalmann Downgrades Zosano Pharma (ZSAN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Zosano Pharma Reports Second Quarter 2016 Financial Results
August 10, 2016 4:15 PM EDTFREMONT, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the second quarter ended June 30, 2016.
With the recent announcement of the first subject treated in our M207 pivotal efficacy trial for acute migraine, we remain on track to report data in Q1 2017, said Dr. Konstantinos Alataris, Zosanos President and Chief Executive Officer. I look forward to providing additional updates as the trial progresses. As of August 8, 2016, 196 subjects were... More
